Congo's Ebola Vaccination Push: What's at Stake in the Latest Outbreak

The Democratic Republic of Congo is no stranger to Ebola. The country has survived more outbreaks than any other nation on Earth—and now it's fighting again. Health authorities have begun vaccinating frontline health workers at the epicenter of a new outbreak, deploying the rVSV-ZEBOV vaccine in a race to contain the virus before it spreads beyond the affected zone.-s[who-ebola-drc]-✦✦✦✦✦✦

What's Happening on the Ground

The current outbreak is centered in a region where healthcare infrastructure is thin and security conditions are difficult—a combination that has historically allowed Ebola to accelerate. Vaccination campaigns in DRC have faced persistent challenges:

• Armed conflict in eastern Congo disrupts supply chains and makes it dangerous for health teams to operate
• Community mistrust of outside medical intervention, rooted in decades of political instability, can slow vaccine uptake
• Remote geography makes cold-chain logistics—keeping vaccines at the right temperature—extremely difficult
• Contact tracing is complicated when population movement is driven by conflict and displacement

Health workers are the priority target for early vaccination precisely because they are most exposed during patient care and, if infected, can become vectors that accelerate an outbreak's spread.

The Vaccine Being Used

The rVSV-ZEBOV vaccine, marketed as Ervebo and developed by Merck, has been a game-changer since it was deployed during the devastating 2018–2020 outbreak in North Kivu—the second-largest Ebola outbreak in history. That outbreak killed over 2,200 people. The vaccine's use through a ring vaccination strategy—immunizing contacts and contacts-of-contacts of confirmed cases—helped eventually bring the outbreak under control despite extraordinary obstacles.

Ervebo received FDA approval in 2019 and WHO prequalification, making it the first licensed Ebola vaccine. A second vaccine, Ad26.ZEBOV/MVA-BN-Filo (Zabdeno/Mvabea), offers a two-dose regimen useful for broader population protection when time allows.

Why This Outbreak Demands Attention

DRC has recorded more than a dozen Ebola outbreaks since the virus was first identified near the Ebola River in 1976. Each one tests the limits of a health system already stretched by endemic diseases like malaria, measles, and mpox—the latter of which DRC is simultaneously battling in a significant outbreak of its own.

The international public health community watches DRC outbreaks closely for several reasons:

• Ebola's case fatality rate can reach 90% without treatment, though modern supportive care and therapeutics like mAb114 and REGN-EB3 have improved survival odds significantly
• Cross-border spread is a real risk given DRC's borders with nine countries
• Each outbreak strains the WHO's Emergency Contingency Fund and pulls resources from other health priorities
• The virus's potential for international spread, demonstrated during the 2014–2016 West Africa epidemic that killed more than 11,000 people, keeps global health officials on alert

The Bigger Picture

Vaccinating health workers first is sound strategy—it protects the people needed to fight the outbreak and sends a signal of institutional commitment to communities that are often skeptical. But vaccination alone won't end an outbreak in a conflict zone. Sustained success requires community engagement, functional surveillance systems, and the kind of political stability that eastern DRC has rarely enjoyed.

The world has better tools to fight Ebola than it did a decade ago. Whether those tools can be deployed fast enough, and trusted enough by affected communities, remains the defining question every time Congo faces this virus again.